Matches in Nanopublications for { ?s ?p "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP646018.RAbPVO7mMZTIEWmDxRlm4Yl0eM86k9hF-m4wmGaVaJ1wQ130_assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646018.RAbPVO7mMZTIEWmDxRlm4Yl0eM86k9hF-m4wmGaVaJ1wQ130_provenance.
- NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646017.RAqdjfYFLLDa4j9BIhHlpP5qyqicvKEqGNsm2wfH6Y6f0130_provenance.
- NP646016.RAPyz1dq5JTdU6VLZjbPkvuqeQFBe8rWg464qAkvzqnkk130_assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646016.RAPyz1dq5JTdU6VLZjbPkvuqeQFBe8rWg464qAkvzqnkk130_provenance.
- NP646019.RAznQcOJpPK7W-9wGTIHSyOW6MNRWVnsehLZZgEO1I2IU130_assertion description "[PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646019.RAznQcOJpPK7W-9wGTIHSyOW6MNRWVnsehLZZgEO1I2IU130_provenance.